No events are scheduled in this topic at this time. Click the RSS icon above and bookmark our RSS feed to learn about future events.
Thursday, October 24, 2013 | 8:30 AM - 7:00 PM
Speakers: Charles H. Adler (Mayo Clinic Arizona / Arizona Parkinson's Disease Consortium), Raymond Bartus (RTBioconsultants, Inc.), Donald E. Frail (AstraZeneca PLC), Reina Fuji, VMD (Genentech Inc.), Kimberley S. Gannon (NeuroPhage Pharmaceuticals, Inc.), Kenneth Marek (Institute for Neurodegenerative Disorders), Mary Maral Mouradian (Rutgers - Robert Wood Johnson Medical School), Adrian Newman-Tancredi (Neurolixis, Inc.), Michael A. Schwarzschild (Massachusetts General Hospital), Eric Siemers (Eli Lilly and Company), Peggy Taylor (Covance Inc.)
Explore emerging basic and translational research that impacts our understanding of Parkinson's Disease and its treatment.
Monday, June 24, 2013 | 10:30 AM - 3:00 PM
Speakers: Yasmine Belkaid (National Institute of Allergy and Infectious Diseases, NIH), Dan R. Littman (New York University School of Medicine), Alexander Rudensky (Memorial Sloan-Kettering Cancer Center)
The Ross Prize, established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine, is awarded to an investigator producing innovative, paradigm-shifting research worthy of significant attention in molecular medicine.
Tuesday, March 12, 2013 | 8:30 AM - 4:30 PM
Speakers: Sheng Bi (Johns Hopkins University School of Medicine), Sheila Collins (Sanford-Burnham Medical Research Institute, Diabetes and Obesity Research Center), Abdul G. Dulloo (University of Fribourg), Vicente Gilsanz (Children's Hospital Los Angeles), Andrew C. Larner (Virginia Commonwealth University), David A. Price, Pfizer, Inc, Devanjan Sikder (Sanford-Burnham Medical Research Institute, Diabetes and Obesity Research Center), J. Enrique Silva (Tufts University School of Medicine), Bruce M Spiegelman (Dana-Farber Cancer Institute, Harvard Medical School), Anne-Ulrike Trendelenburg (Novartis Institutes for BioMedical Research, Yu-Hua Tseng (Joslin Diabetes Center, Harvard Medical School), Richard L. Veech (National Institute on Alcohol Abuse and Alcoholism/NIH)
This conference will present recent research exploring adipogenesis focusing on brown adipose tissue, and will explore its implications in diet-induced obesity.
June 26 - 27, 2012
Organizers: William G. Kerr (SUNY Upstate Medical University), Christina Mitchell (Monash University, Australia), and Christian Rommel (Intellikine)
Keynote Speaker: Lewis C. Cantley (Harvard Medical School)
Examine the role of Inositol Phospholipid (IP) signaling in cancer, metabolic, and inflammatory disease. This exploration of the specificity and interplay of diverse IP-modifying enzymes aims to identify novel approaches for therapeutic intervention.
Edited by Annals of the New York Academy of Sciences
This Annals volume presents short reviews of the functions of brown adipose tissue and its potential therapeutic value in obesity management.
Edited by Jaime Uribarri
(Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York)
This Annals volume explores the health implications of high dietary phosphorus intake for the general population and the current evidence associating excess phosphorus intake with potential risk for disease.
Free online access provided by the Sackler Institute for Nutrition Science
Edited by Robert Giuli
(Deputy Director of OESO, Executive Director of the OESO Foundation, Paris, France) and Asad Umar
(National Cancer Institute, Rockville, Maryland)
This Annals volume presents a compilation of expert views on topics related to esophagus physiology and disease presented at the World Organization for Specialized Studies on Diseases of the Esophagus 11th World Conference.
Organizers: Michael Krams (Janssen Pharmaceuticals), Michael Poole (AstraZeneca), Michael T. Ropacki (Janssen Alzheimer Immunotherapy), Reisa A. Sperling (Harvard Medical School), Sonya Dougal (formerly at The New York Academy of Sciences), and Diana L. van de Hoef (The New York Academy of Sciences)
This eBriefing documents a workshop that considered how to implement an adaptive trial design for AD.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.